Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05406960
Other study ID # FMSELMI
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 10, 2019
Est. completion date February 10, 2021

Study information

Verified date June 2022
Source Faculty of Medicine, Sousse
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an interventional, non-randomized, controlled, pilot study that explores a new approach to treat, Abnormal uterine bleeding-menometrorrhagia in women, being candidates for hysterectomy, based on tea infusion consumption of a mixture of two plants.


Description:

Menometrorrhagia is excessive uterine bleeding resulting from a combination of two different conditions, namely menorrhagia, which is heavy bleeding during the menstrual period, and metrorrhagia, when the period lasts more than seven days or when uterine bleeding exists between periods. It is defined as abnormal uterine bleeding (AUB) and it is a worldwide health problem affecting 11 to 13% of the general female population in the reproductive age and increasing up to 24% in women aged 40-50 years. Conventional treatment of menometrorrhagia consists of symptomatic treatment including tranexamic acid and levonorgestrel intrauterine device. If the first-line medication fails to treat women with AUB, surgical treatment such as a hysterectomy could be necessary. However, both medical treatments and surgical procedures have different side effects, including gastrointestinal symptoms, liver disease, obesity, and thromboembolic diseases. Moreover, the hypoestrogenic state of these therapies can also lead to rapid bone demineralization and menopausal symptoms, such as vaginal dryness and hot flushes, having a negative effect on women's quality of life. Thus, because of these serious side effects, it seems logical to investigate other available sources. Such problems may be beyond the scope of herbal treatment. Mentha pulegium is a perennial plant from the Lamiaceae family, also known as Pennyroyal, and is used in pharmaceutical and agro-alimentary industries. Artemisia abrotanum L, commonly known as Southernwood, is a small bushy shrub with small, feathery, narrow, and grey-green leaves. The genus belongs to the Asteraceae family. A mixture of these two herbs is known as a strong emmenagogue. Data collection: The plants used in this study were collected through an ethnobotanical survey. The data on the plants' studies were collected through an internet search in: Medicinal plants mentioned in Canon www., www. Science Direct, www.pubmed.com. , www. Scopus, www.wiley.com, www. Google scholar, www. web of science, books in phytotherapy All details with regard to : - The effect of the treatment on the menstrual cycle - Menstruation duration - Adverse effects - Bleeding intensity measured using Pictorial Blood Assessment Chart during three consecutive menstrual treatments and the three-month follow-up. will be collected from participants by phone Details about the Follow-up: Allocated to intervention : Follow-up (Visit 2): Phone or direct contact after the end of oral administration (day 3) for clinical response evaluation. Phone or direct contact one week after treatment Follow-up 3: Phone or direct contact after the end of oral administration (day 3) for clinical response evaluation. Phone or direct contact one week after treatment Follow-up (Visit 4): Phone or direct contact after the end of oral administration (day 3) for clinical response evaluation. Phone or direct contact one week after treatment VISIT 5 (closing visit) Statistical Analysis Data entry and analysis will be performed using ( IBMV SPSS R 20.0). To test for normality and distribution of the variables. A significance level of a p-value of less than 0.05 will be considered Descriptive statistics will be used to examine the characteristics of the study population (means, standard deviation). Comparison of the biological parameters and scores of PBAC between baseline and the end of treatment will be performed using paired t-test when variables are normally distributed and Wilcoxon signed ranks test, as a non-parametric test when variables are not normally distributed. Sample size The sample size will be assessed according to the following formula N = (Zα/2) 2 s2 /d2, where "s" is the standard deviation (SD ). "d" is the accuracy of the estimate. "Zα/2" is the normal deviate for a two-tailed alternative hypothesis at a level of significance.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date February 10, 2021
Est. primary completion date December 20, 2020
Accepts healthy volunteers No
Gender Female
Age group 30 Years to 55 Years
Eligibility Inclusion Criteria: - Women failed first-line intervention to stop bleeding and planned for hysterectomy - Women between (30-50 years) - Able to understand and provide informed consent to participate in the study. - Not pregnant or lactating - Having menstrual period more than 7 days with uterine bleeding at irregular intervals. Exclusion Criteria: Participants with at least one of the following criteria will not be included in the trial: - Chronic disease with long-term treatment (i.e. asthma, cardiovascular disorders..) - woman taking any standard medications for abnormal uterine bleeding - Women who have a history of gastrointestinal bleeding or ulcer - Women who have abnormal kidney function - Participants with increasing menstrual bleeding during the treatment requires surgical emergency procedures. - Those refusing the instructions or participating in other clinical trials. - Participant take other herbal treatment - - Age less than 18 years - - Healthy Volunteers - women with ovarian tumours

Study Design


Intervention

Dietary Supplement:
Tea infusion
Herbal tea infusion will be administrated by the oral route before food

Locations

Country Name City State
Tunisia faculty of medicine Sousse Sousse

Sponsors (2)

Lead Sponsor Collaborator
Faculty of Medicine, Sousse Centre Hôpital Universitaire Farhat Hached

Country where clinical trial is conducted

Tunisia, 

References & Publications (14)

Bone, K., and Mills, S. Principles and practice of phytotherapy: Modern Herbal Medicine. Churchill Livingstone.2nd ed. Londo n: Elsevier. 2013; 9780702052972

Chopra, R.N, Nayar S.L, Chopra, I.C. Glossary of Indian Medicinal Plant, New Delhi. CSIR.1956 .1-330.

Donnez J, Squifflet J, Donnez O. Minimally invasive gynecologic procedures. Curr Opin Obstet Gynecol. 2011 Aug;23(4):289-95. doi: 10.1097/GCO.0b013e328348a283. Review. — View Citation

European Tea Committee (ETC), European Herbal Infusions Association (EHIA).Inventory List of Herbals Considered as Food. 2016 Available at: https://thie-online.eu/files/thie/docs/2019-09-26_PU_THIE_Inventory_List_status_27-06-2019_final.pdf

Fraser IS, Critchley HO, Munro MG, Broder M. Can we achieve international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding? Hum Reprod. 2007 Mar;22(3):635-43. Epub 2007 Jan 4. — View Citation

Hoffmann TC, Montori VM, Del Mar C. The connection between evidence-based medicine and shared decision making. JAMA. 2014 Oct 1;312(13):1295-6. doi: 10.1001/jama.2014.10186. — View Citation

Istre O, Langebrekke A, Qvigstad E. Changing hysterectomy technique from open abdominal to laparoscopic: new trend in Oslo, Norway. J Minim Invasive Gynecol. 2007 Jan-Feb;14(1):74-7. — View Citation

Jazani NH, Ghasemnejad-Berenji H, Sadegpoor S. Antibacterial effects of Iranian Mentha pulegium essential oil on isolates of Klebsiella sp. Pak J Biol Sci. 2009 Jan 15;12(2):183-5. — View Citation

Kang M, Ragan BG, Park JH. Issues in outcomes research: an overview of randomization techniques for clinical trials. J Athl Train. 2008 Apr-Jun;43(2):215-21. doi: 10.4085/1062-6050-43.2.215. — View Citation

Kowalski R, Wawrzykowski J, Zawislak G.Analysis of essential oils and extracts from Artemisia abrotanum L. and Artemisia dracunculus L. Herba Pol.2007.53: 246-254.

Oueslati, S, Karray-Bouraoui, N, Attia, H. et al. Physiological and antioxidant responses of Mentha pulegium (Pennyroyal) to salt stress. Acta Physiol Plant 32. 2010.289-296. https://doi.org/10.1007/s11738-009-0406-0

Qaraaty M, Kamali SH, Dabaghian FH, Zafarghandi N, Mokaberinejad R, Mobli M, Amin G, Naseri M, Kamalinejad M, Amin M, Ghaseminejad A, HosseiniKhabiri SJ, Talei D. Effect of myrtle fruit syrup on abnormal uterine bleeding: a randomized double-blind, placebo-controlled pilot study. Daru. 2014 Jun 2;22:45. doi: 10.1186/2008-2231-22-45. — View Citation

Sutour S, Bradesi P, Casanova J, Tomi F. Composition and chemical variability of Mentha suaveolens ssp. suaveolens and M. suaveolens ssp. insularis from Corsica. Chem Biodivers. 2010 Apr;7(4):1002-8. doi: 10.1002/cbdv.200900365. — View Citation

Teri Moser Woo, Marylou Robinson.Pharmaco therapeutics for Advance Practice Nurse Prescribers. Library of Congress. (2016:138-1520.

* Note: There are 14 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Reduce the menstrual duration in days the Pictorial Blood Loss Assessment Chart (PBLAC) the number of bleeding day during menstruation 180 days
Primary Reduce the bleeding abundance bleeding abundance will be measured by the Pictorial Blood Loss Assessment Chart (PBLAC) The total score is calculated by adding up the sum of all scores for the sanitary pads used in the menstrual cycle. : 1 for lightly stained, 5 for moderately soiled, and 20 for completely saturated pads. Clots were given a score of 1 for small and 5 for large clots.
Abnormal PBLAC bleeding score greater than or equal to 100, which correlates with bleeding abundance, defined as greater than 80 mL of menstrual blood loss. Normal bleeding is defined as a score of 75 or less. A score of 0 indicates amenorrhea or the absence of menstruation.
180 days
Secondary Change From Baseline in Hematocrit (Hct) Concentrations at Treatment Day 90 Hematocrit was measured before treatment and after 90 days at the end of treatment 180 days
Secondary Change From Baseline in Hemoglobin Concentration at Treatment Day 90 Hemoglobin was measured before treatment and after 90 day A positive value indicates an increase in hemoglobin from baseline at treatment day 90 90 days
Secondary Change From Baseline in Fibrinogen Concentration at Treatment Day 90 Fibrinogen Concentration was measured before treatment and after 90 day 90 days
Secondary Change From Baseline in Prothrombin Time at Treatment Day 90 Prothrombin Time was measured before treatment and after 90 day 90 days
Secondary hange From Baseline in serum Creatinine Time at Treatment Day 90 to detect urinary toxicity. conducted at the start of the trial and after the last infusion consumption days 90 90 days
See also
  Status Clinical Trial Phase
Recruiting NCT05337566 - Does Additional Use of Preoperative Azithromycin Decrease Posthysterectomy Infections N/A
Recruiting NCT04130464 - Intraperitoneal Infusion of Analgesic for Postoperative Pain Management Phase 4
Recruiting NCT05537727 - Robotic MIS With Dexter
Completed NCT05037383 - Motion and Viewing Analysis of Surgeons During Minimally Invasive Gynecological Interventions N/A
Completed NCT04080323 - Single-dose Vaginal Dinoprostone and Hysterectomy Phase 3
Not yet recruiting NCT06011538 - Web-based Versus Standard Information for Same Day Hysterectomy (WISH) N/A
Completed NCT03187327 - Feasibility of Opportunistic Salpingectomy at the Time of Vaginal Hysterectomy for Benign Pathology N/A
Completed NCT00528177 - Morphine vs. Oxycodone for Postoperative Pain Management Phase 4
Terminated NCT00551785 - Surveillance Study of Women Taking Intrinsa® Phase 4
Completed NCT03641625 - Effect of SmtO2 Guided Care on PONV (iMODIPONV) N/A
Terminated NCT03500744 - Erector Spinae Plane Block for Major Gynecologic and Urologic Surgery N/A
Recruiting NCT03294343 - Risk-Reducing Surgeries for Hereditary Ovarian Cancer N/A
Completed NCT03610425 - A Standardized Bundle Protocol to Optimize Outcomes With Patients Undergoing Gynecological Surgery
Completed NCT05659303 - Evaluation of an Outpatient Protocol in Patients Operated for Laparoscopic Hysterectomy
Completed NCT05270447 - Short-Term Effects of Connective Tissue Massage After Hysterectomy N/A
Recruiting NCT05031182 - Tolerance of the vNOTES Surgical Technique in Total Hysterectomy for Benign Lesion. Clinical Trial of Non-inferiority Compared to the Laparoscopic Technique. N/A
Completed NCT03634306 - Ultravision Visual Clearing System in Laparoscopic Hysterectomy and Myomectomy N/A
Completed NCT01526668 - Follow-up Strategies for Improved Postoperative Recovery After Benign Hysterectomy N/A
Recruiting NCT05374720 - Analysis of the Molecular Composition of Tubal Cilia in Patients With or Without Ectopic Pregnancy N/A
Recruiting NCT04109989 - Clinical Assessment - HominisTM Surgical System N/A